click below
click below
Normal Size Small Size show me how
DU PA IBS
Duke PA Irritable Bowel Syndrome
| Question | Answer |
|---|---|
| IBS affects mostly | women |
| IBS peaks in the __ decade of life | 3-4th |
| onset of IBS after age __ is unusual | 50 |
| IBS is characterized by | chronic abdominal pain and bloating relieved by defecation. Changes in stool frequency or appearance in the stool |
| comorbid conditions associated with IBS | Gerd, genito-urinary symptoms, fibromyalgia, headache, backache, psychological symptoms |
| patient has hard stools more than 25% of the time and loose stools less than 25% of the time | IBS-C |
| patient has loose stools more than 25% of the time and hard stools less than 25% of the time | IBS-D |
| don't do a sigmoidoscopy in a patient after the age of __ do a colonoscopy instead | 50 |
| patients with IBS should not have __ | bloody stools |
| balloon distension studies of the rectosigmoid colon and ileum show patients with IBS __ | experience pain and bloating at balloon volumes and pressures significantly lower than thos that induce pain in controls |
| lowered rectal __ is considered a hallmark of IBS | pain threshold |
| 50% of IBS patients who seek medical attention are __ | depressed or anxious |
| the presence or absence of a history of __ is correlated in the severity of symptoms in patients with IBS | childhood abuse |
| administration of __ was proven to exacerbate symptoms especially bloating | enteral fats |
| postinfectious IBS is seen in infection with | entamoeba, salmonella, and campylobacter |
| overall, __ appear similar to placebo in the treatment of IBS | bulking agents |
| antispasmodics: angents such as __ are thought to reduce abdominal pain or bloating through anti-cholinergic pathways | dicyclomine, hyoscyamine |
| those with constipation predominant IBS may benefit from __ | osmotic laxatives |
| data from RCT's show __ decrease global symptoms and reduce pain | antispasmodics |
| Stimulate receptors in the enteric nervous system that inhibit peristalsis and fluid secretion | anti-diarrheals |
| __ decrease stool frequency and improved consistency but not abdominal pain or global IBS symptoms | anti-diarrheals |
| Benefit of improved global symptoms seen in IBS-D but not IBS-C | antidepressants |
| RCTs show improved coping after __ but no change in bowel symptoms | psychological treatment |
| Several small, short term studies with __ most with no benefit over placebo | lactobacillus |
| Most recent trial with encapsulated probiotic __ found to be superior with improvement in global symptoms exceeding placebo by 20%. | Bifidobacterium infantis 35624 |
| Major regulator of the peristalsic reflex and sensory relays in the gut through 5HT3 and 5HT4 receptors. No longer on the market in the US | Zelnorm |
| locally acting selective chloride-channel activator that enhances chloride-rich fluid secretion into the intestinal lumen. Approved by FDA for use in IBS-C | Lubiprostone (amitiza) |
| treatment approach for mild IBS (no hinderance on daily life, no missed work or school) | patient education, reassurance, dietary recommendations |